CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性 B 细胞前体急性淋巴细胞白血病儿童患者接受 blinatumomab 治疗前后的 CD19 表达
英文原题：CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab.
查看英文原题
CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
贝林妥欧单抗是一种双特异性T细胞衔接器（BiTE）免疫肿瘤药物，在复发/难治性B细胞前体急性淋巴细胞白血病（R/R B-ALL）患者中显示出显著活性，但仍有部分患者复发。监测复发患者的分化抗原19（CD19）表达，对指导后续治疗的顺序至关重要。本研究分析了59名儿童R/R B-ALL患者在确诊R/R B-ALL当天，以及贝林妥欧单抗第1周期第15天和第29天的CD19表达。接受1个周期贝林妥欧单抗治疗的大多数患者仍保留CD19表达，因此仍适合后续接受抗CD19 CAR-T 细胞治疗。
展开英文摘要原文
Blinatumomab is a BiTE (bispecific T-cell engager) immuno-oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL); however, a subset of patients relapse. Monitoring expression of cluster of differentiation (CD)19 in relapsed patients is critical to inform sequencing of subsequent therapies.
The expression of CD19 in 59 pediatric patients with R/R B-ALL was analyzed on the day of diagnosis of R/R B-ALL and on days 15 and 29 of cycle 1 of blinatumomab. Most patients treated with one cycle of blinatumomab retained expression of CD19, and would therefore be eligible for subsequent anti-CD19 CAR T-cell therapy.
论文信息
- 作者
- Mejstrikova E、Klinger M、Markovic A、Zugmaier G、Locatelli F
- 第一作者单位
- Department of Pediatric Hematology/Oncology, CLIP, Charles University, University Hospital Motol, Prague, Czech Republic.Czechia
- 通讯作者单位
- Department of Pediatric Hematology-Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.Italy
- 文献类型
- 非美国政府资助研究
- 期刊
- Pediatric blood & cancer2021 Dec
- 原文标识
- PubMed 34519430 · DOI 10.1002/pbc.29323